康寧傑瑞製藥-B(09966.HK)於美國臨床腫瘤學會年會展示癌症藥物臨床研究結果
康寧傑瑞製藥-B(09966.HK)公布,將於2022年美國臨床腫瘤學會年會(ASCO)展示KN046及KN026的最新研究情況,摘要自美國東部夏令時間5月26日下午5時正公布,壁報展示將於美國中部夏令時間6月4日上午8時正至上午11時正進行。
公司指出,是次披露的包括KN046單藥作為不可切除局部晚期或轉移性PDAC二線及以上治療方案的II期臨床試驗研究結果,KN046聯合侖伐替尼用於治療晚期不可切除或轉移性HCC的II期臨床試驗(KN046-IST-05)最新研究結果,KN046(集團研發的一種重組人源化PD-L1/CTLA-4雙特異性抗體)聯合白蛋白紫杉醇/吉西他濱治療晚期胰腺癌的III期關鍵臨床試驗設計,在免疫檢查點抑制劑方面治療失敗的胸腺癌患者的KN046 II期研究,及KN026(集團研發的一種HER2靶向雙特異性抗體)單藥治療以往曾接受治療的晚期HER2表達GC/GEJ患者的II期研究結果。
此外,有關公司於今年2月15日向向2022年ASCO年會提交有關KN046-IST-05的若干臨床數據摘要,公司在後續數據審查中發現安全性數據及死亡病例歸因異常,並於4月11日與研究者申請撤回摘要,惟摘要未成功撤回。公司澄清,經研究者確認,KN046-IST-05中只有一例患者死亡可能與KN046有關,而其他三例患者死亡則與之無關。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.